BACKGROUND: Coinfection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is common in Africa; however, the impact of HBV infection on the outcomes of antiretroviral therapy programs is unclear. We evaluated the impact of chronic hepatitis B on HIV virologic response, changes in CD4 cell count, hepatotoxicity, and mortality among Africans receiving highly active antiretroviral therapy (HAART). METHODS: We conducted a retrospective cohort study involving a workplace HAART program in South Africa. Participants received HAART according to a protocol and were followed up for up to 72 weeks. On the basis of pre-HAART serum assays, patients were classified as being hepatitis B surface antigen (HBsAg) negative, HBsAg positive with a low HBV DNA level (</= 1 x 10(4) copies/mL), and HBsAg positive with a high HBV DNA level (> 1 x 10(4) copies/mL). The relationships between HBV status and HIV RNA suppression, change in CD4 cell count, mortality, and hepatotoxicity were assessed with use of regression techniques. RESULTS: Five hundred thirty-seven individuals fulfilled the inclusion criteria; 431 (80.3%) of these patients were HBsAg negative, 60 (11.2%) were HBsAg positive with a low HBV DNA level, and 46 (8.6%) were HBsAg positive with a high HBV DNA level. All groups had similar rates of HIV RNA suppression (P = .61), CD4 cell count increases (P =.75), and mortality (17 total deaths; P=.11) for up to 72 weeks after the initiation of HAART. Baseline transaminase levels were highest in the group with high HBV DNA levels (P=.004). Hepatotoxicity was similar between the HBsAg-negative group and the group with low HBV DNA levels but was higher in the group with high HBV DNA levels (incidence rate ratio, 4.4). CONCLUSIONS: We revealed that HBV status does not affect HIV RNA suppression, CD4 cell count response, or mortality during the first 72 weeks of HAART in an African setting. The risk of HBV-associated hepatotoxicity, however, is associated with the baseline HBV DNA level.
BACKGROUND: Coinfection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is common in Africa; however, the impact of HBV infection on the outcomes of antiretroviral therapy programs is unclear. We evaluated the impact of chronic hepatitis B on HIV virologic response, changes in CD4 cell count, hepatotoxicity, and mortality among Africans receiving highly active antiretroviral therapy (HAART). METHODS: We conducted a retrospective cohort study involving a workplace HAART program in South Africa. Participants received HAART according to a protocol and were followed up for up to 72 weeks. On the basis of pre-HAART serum assays, patients were classified as being hepatitis B surface antigen (HBsAg) negative, HBsAg positive with a low HBV DNA level (</= 1 x 10(4) copies/mL), and HBsAg positive with a high HBV DNA level (> 1 x 10(4) copies/mL). The relationships between HBV status and HIV RNA suppression, change in CD4 cell count, mortality, and hepatotoxicity were assessed with use of regression techniques. RESULTS: Five hundred thirty-seven individuals fulfilled the inclusion criteria; 431 (80.3%) of these patients were HBsAg negative, 60 (11.2%) were HBsAg positive with a low HBV DNA level, and 46 (8.6%) were HBsAg positive with a high HBV DNA level. All groups had similar rates of HIV RNA suppression (P = .61), CD4 cell count increases (P =.75), and mortality (17 total deaths; P=.11) for up to 72 weeks after the initiation of HAART. Baseline transaminase levels were highest in the group with high HBV DNA levels (P=.004). Hepatotoxicity was similar between the HBsAg-negative group and the group with low HBV DNA levels but was higher in the group with high HBV DNA levels (incidence rate ratio, 4.4). CONCLUSIONS: We revealed that HBV status does not affect HIV RNA suppression, CD4 cell count response, or mortality during the first 72 weeks of HAART in an African setting. The risk of HBV-associated hepatotoxicity, however, is associated with the baseline HBV DNA level.
Authors: Miguel Goicoechea; Davey M Smith; Lin Liu; Susanne May; Allan R Tenorio; Caroline C Ignacio; Alan Landay; Richard Haubrich Journal: J Infect Dis Date: 2006-05-18 Impact factor: 5.226
Authors: Deborah Konopnicki; Amanda Mocroft; S de Wit; Francisco Antunes; Bruno Ledergerber; Christine Katlama; K Zilmer; Stefano Vella; Ole Kirk; Jens D Lundgren Journal: AIDS Date: 2005-03-24 Impact factor: 4.177
Authors: W Phillip Law; Chris J Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper; Gregory J Dore Journal: AIDS Date: 2004-05-21 Impact factor: 4.177
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: M J Vinikoor; K Musukuma; V Munamunungu; M Masaninga; I Sikazwe; B H Chi; G Wandeler Journal: J Viral Hepat Date: 2015-03-17 Impact factor: 3.728
Authors: H N Kim; J Scott; A Cent; L Cook; R A Morrow; B Richardson; K Tapia; K R Jerome; G Lule; G John-Stewart; M H Chung Journal: J Viral Hepat Date: 2011-05-13 Impact factor: 3.728
Authors: Chloe L Thio; Laura Smeaton; Melissa Saulynas; Hyon Hwang; Shanmugam Saravanan; Shanmugam Saravan; Smita Kulkarni; James Hakim; Mulinda Nyirenda; Hussain S Iqbal; Umesh G Lalloo; Anand S Mehta; Kimberly Hollabaugh; Thomas B Campbell; Shahin Lockman; Judith S Currier Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José M Peña; José V Fernández-Montero; Laura Benítez; Isabella Esposito; Pablo Barreiro Journal: Curr HIV/AIDS Rep Date: 2015-09 Impact factor: 5.071
Authors: Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte Journal: BMC Public Health Date: 2010-03-01 Impact factor: 3.295
Authors: V Mave; D Kadam; A Kinikar; N Gupte; D Bhattacharya; R Bharadwaj; K McIntire; V Kulkarni; U Balasubramanian; N Suryavanshi; C Thio; P Deshpande; J Sastry; R Bollinger; A Gupta; R Bhosale Journal: HIV Med Date: 2014-01-14 Impact factor: 3.180